These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17445122)

  • 21. High-titer inhibitor development in hemophilia A: lack of product specificity.
    Hoots WK; Lusher J
    J Thromb Haemost; 2004 Feb; 2(2):358-9. PubMed ID: 14996014
    [No Abstract]   [Full Text] [Related]  

  • 22. Factor VIII inhibitors--an algorithmic approach to treatment.
    Kessler CM
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):33-6. PubMed ID: 7939771
    [No Abstract]   [Full Text] [Related]  

  • 23. Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab.
    Miller CH; Boylan B; Payne AB; Driggers J; Bean CJ
    Int J Lab Hematol; 2021 Apr; 43(2):e84-e86. PubMed ID: 33174329
    [No Abstract]   [Full Text] [Related]  

  • 24. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry.
    Kruse-Jarres R; Gilsenan A; Spears J; Kaye JA
    Haemophilia; 2015 Mar; 21(2):e122-e124. PubMed ID: 25623889
    [No Abstract]   [Full Text] [Related]  

  • 25. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
    Rangarajan S; Jiménez-Yuste V; Santagostino E
    Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
    [No Abstract]   [Full Text] [Related]  

  • 26. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of factor VIII: detection and treatment.
    Brettler DB
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():21-5. PubMed ID: 7886576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
    Kessler CM; Ludlam CA
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
    [No Abstract]   [Full Text] [Related]  

  • 30. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors.
    Tarantino M; Aledort L
    Transfusion; 2001 Dec; 41(12):1628-9. PubMed ID: 11778084
    [No Abstract]   [Full Text] [Related]  

  • 31. Markers for the factor VIII antibody response in hemophilia A.
    Shapiro SS
    Scand J Haematol Suppl; 1984; 40():181-5. PubMed ID: 6433450
    [No Abstract]   [Full Text] [Related]  

  • 32. Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A.
    McFadyen JD; Tran H; Kaplan ZS
    Br J Haematol; 2017 Sep; 178(6):986-987. PubMed ID: 27431860
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinically significant inhibitors in hemophilia A patients from India tend to persist.
    Shetty S; Ghosh K; Pathare A; Mohanty D
    Acta Haematol; 2000; 103(3):175-6. PubMed ID: 10940659
    [No Abstract]   [Full Text] [Related]  

  • 34. More on: mild hemophilia A and inhibitor development.
    Koestenberger M; Leschnik B; Muntean W
    J Thromb Haemost; 2004 Apr; 2(4):676; author reply 677. PubMed ID: 15102028
    [No Abstract]   [Full Text] [Related]  

  • 35. Immune tolerance in haemophilia and the treatment of haemophiliacs with an inhibitor. Proceedings of the 2nd Workshop on Immune Tolerance. Bonn-Konigswinter, Germany, August 27-30, 1997.
    Vox Sang; 1999; 77 Suppl 1():1-100. PubMed ID: 10644229
    [No Abstract]   [Full Text] [Related]  

  • 36. Transient inhibitors in the Recombinate PUP study.
    Rothschild C; Gill J; Scharrer I; Bray G
    Thromb Haemost; 2000 Jul; 84(1):145-6. PubMed ID: 10928491
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
    Lusher JM
    Vox Sang; 1999; 77 Suppl 1():9. PubMed ID: 10529677
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune tolerance for the treatment of factor VIII inhibitors--twenty years' 'bonn protocol'.
    Brackmann HH; Oldenburg J; Schwaab R
    Vox Sang; 1996; 70 Suppl 1():30-5. PubMed ID: 8869466
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols.
    Mariani G; Scheibel E; Nogao T; Kasper CK; Ewing NP; Mauser-Bunschoten E; Ghirardini A; Bellocco R; Brackman HH
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):62-4. PubMed ID: 7939781
    [No Abstract]   [Full Text] [Related]  

  • 40. Advances in the treatment of hemophilia.
    Kessler CM
    Clin Adv Hematol Oncol; 2008 Mar; 6(3):184-7. PubMed ID: 18391917
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.